Citadel Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

Citadel Advisors’s Portfolio XPH Stock Details XPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,200	Closed	-$96.4K	–	15417
2025 Q1	$96.4K	Sell	2,200 -14,100	-87%	-$622K	﹤0.01%	11530
2024 Q4	$701K	Buy	16,300 +6,300	+63%	+$286K	﹤0.01%	7826
2024 Q3	$444K	Sell	10,000 -7,000	-41%	-$300K	﹤0.01%	8513
2024 Q2	$676K	Sell	17,000 -3,700	-18%	-$150K	﹤0.01%	7418
2024 Q1	$893K	Buy	20,700 +7,300	+54%	+$315K	﹤0.01%	7150
2023 Q4	$558K	Sell	13,400 -4,700	-26%	-$178K	﹤0.01%	7863
2023 Q3	$719K	Buy	18,100 +7,900	+77%	+$334K	﹤0.01%	7281
2023 Q2	$418K	Buy	10,200 +9,900	+3,300%	+$409K	﹤0.01%	8328
2023 Q1	$12.3K	Buy	300 +100	+50%	+$4.2K	﹤0.01%	13418
2022 Q4	$8.19K	Buy	+200	New	+$8.33K	﹤0.01%	13761

Other funds holding XPH

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

KWM

Kingsview Wealth Management Grants Pass, Oregon $8.25B AUM 24.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners London $46.9B AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Citadel Advisors's XPH Position: Q2 2026 in Review

Citadel Advisors sold out of State Street SPDR S&P Pharmaceuticals ETF (XPH) in Q2 2026, closing a stake of 40,874 shares — an estimated $2.21M sold.

Citadel Advisors first reported a position in XPH in Q1 2014 and held it in 37 quarters. The position peaked at $3.97M in Q4 2025. 92 funds tracked by Wall St. Rank hold XPH as of Q2 2026.

Citadel Advisors reported no remaining State Street SPDR S&P Pharmaceuticals ETF position as of Q2 2026 after selling out during the quarter.
Citadel Advisors sold 40,874 State Street SPDR S&P Pharmaceuticals ETF shares in Q2 2026, an estimated $2.21M.
Citadel Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2014 and held it in 37 quarters.
Citadel Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $3.97M in Q4 2025.
92 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.